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Abstract
Background: The use of thermocoagulation for the treatment of cervical precancerous lesions has recently generated a
great deal of interest. Our aim was to determine the feasibility of this outpatient procedure in the context of a cervical
cancer (CC) screen-and-treat campaign in sub-Saharan Africa.
Methods: Between July and December 2015, women living in the area of Dschang (Cameroon) aged between 30 and
49 years, were enrolled in a CC screening study.
HPV self-sampling was performed as a primary screening test and women who were either “HPV 16/18/45-positive” or
“positive to other HPV types and to VIA” were considered screen-positive, thus requiring further management. The
primary outcome was the percentage of screen-positive patients who met the criteria to undergo thermocoagulation.
The secondary outcome was the assessment of the procedure’s side effects immediately after treatment and at the 1-
month follow-up visit.
Results: A total of 1012 women were recruited in the study period. Among 121 screen-positive women, 110 of them
(90.9%) were eligible to be treated with thermocoagulation. No patients discontinued treatment because of pain or
other side effects. The mean ± SD (Standard Deviation) score measured on the 10-point Visual Analogue Scale
(VAS) was 3.0 ± 1.6. Women having less than 2 children were more likely to report a higher pain score than those
with more than two (4.2 ± 2.0 versus 2.9 ± 1.5, respectively; p value = 0.016). A total of 109/110 (99.1%) patients
came to the 1-month follow-up visit. Vaginal discharge was reported in 108/109 (99.1%) patients throughout the
month following treatment. Three patients (2.8%) developed vaginal infection requiring local antibiotics. No
hospitalizations were required.
Conclusion: The majority of screen-positive women met the criteria and could be treated by thermocoagulation.
The procedure was associated to minor side effects and is overall feasible in the context of a CC screen-and-treat
campaign in sub-Saharan Africa.
Trial registration: The trial was retrospectively registered on November 11, 2015 with the identifier: ISRCTN99459678.
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Précis
Thermocoagulation is a feasible approach for the treatment
cervical precancerous lesions in the low-resource context
of sub-Saharan Africa.
Background
Cervical cancer (CC) represents the fourth most com-
mon cancer among women worldwide [1]. Nevertheless,
the global distribution of CC’s burden is marked by a
significant disparity, with over 80% of cases occurring in
low and medium-income countries (LMIC) [1]. Such
disproportion is likely due to the difficulties in the
implementation of a cytology-based screening program,
which requires multiple-day, long-distance visits and
important human and financial resources [2]. The avail-
ability of Point-of-Care technologies and visual inspection
methods is progressively changing our understanding of
CC screening and giving way to the possibility of of-
fering screening and, if needed, treatment in a 1-day
session [3, 4]. This same-day screen-and-treat strategy
has proven to be more effective than cytology-based
screening in terms of both patient compliance and
costs [5]. In order to increase the screening strategy’s
effectiveness, the choice of an appropriate treatment,
which should be well accepted by women while guar-
anteeing satisfactory cure rates, is fundamental.
Excisional procedures such as Loop Electrosurgical
Excision Procedure (LEEP) require trained personnel
and expensive infrastructures, which makes them scarcely
applicable in LMIC. Two low-cost and simple treatment
methods are represented by cryotherapy and thermocoagu-
lation. Cryotherapy is a highly effective intervention with a
good cure rate, but the low availability of refrigerant gas
makes its use challenging in LMIC [6]. In the given con-
text, thermocoagulation may represent an attractive alter-
native for the treatment of cervical precancerous lesions.
Thermocoagulation has been available for several
decades in Western countries. A recent meta-analysis in-
cluding studies conducted mainly in industrialized coun-
tries has shown that the use of thermocoagulation for
the treatment of CIN is as effective as other methods,
such as cryotherapy and LEEP, with the advantage of
being rapid and associated to a low occurrence of side
effects [7]. This method may be of particular interest in
the context of LMIC although to date, despite the
growing interest and focus on this type of therapy,
very little has been published about its use in devel-
oping countries.
An issue of particular interest is to determine, in the con-
text of a screening campaign conducted in a low-resource
setting, the percentage of screen-positive patients who meet
the criteria to undergo thermocoagulation, as well as the
side effects that can disrupt the procedure. These data
would enable us to plan the allocation of resources in order
to embody the procedure in a resource-constrained setting.
Our aim was to conduct a pragmatic analysis evaluat-
ing the feasibility of thermocoagulation in the context of
a CC screen-and-treat campaign in sub-Saharan Africa.
Methods
Study setting
The Faculty of Medicine and Biomedical Sciences,
Yaoundé, the National Committee for fight against cancer,
Cameroon, the University of Dschang, Cameroon and the
Geneva University Hospitals currently work together to
evaluate innovative cervical cancer screening options in
order to develop a screening approach adapted to the
needs and means of people in Cameroon. This prospective
study is part of this collaborative platform, which has
been approved by the National Ethics Committee of
Cameroon (2015/02/559/CE/CNERSH/SP) and by the
Ethical Cantonal Board of Geneva, Switzerland (CCER
15–068). The study has been conducted at the District
Hospital of Dschang, Cameroon. All participants were
asked to sign a written informed consent form before
taking part to the study. Assistance for data manage-
ment was provided by the CRC (Centre de Recherche
Clinique) of the Geneva University Hospitals.
Study participants and procedure
Women aged between 30 and 49 years, interested to par-
ticipate in a CC screening campaign were thoroughly in-
formed about cervical cancer (basic facts, prevention,
detection, treatment) and the study’s procedure. Exclusion
criteria were pregnancy and previous total hysterectomy.
The health care providers instructed all enrolled women
on how to perform HPV self-sampling using a dry cotton
swab (TCSSwabs, Technical Service Consultants Ltd, Lan-
cashire, UK). The participants were told to gently unscrew
the cap of the plastic tube in order to remove the dry
swab. They then had to insert the soft-tip end of the swab
into the vagina while being careful to avoid contact with
external genitalia. When resistance was met (at about 5–
6 cm), they had to gently turn the swab from three to five
times clockwise and counterclockwise. Subsequently, the
swab had to be placed back into the plastic tube. The pro-
cedure was performed by the women themselves.
The cervico-vaginal samples collected by the women
were promptly analyzed with the HPV GeneXpert machine
(GeneXpert®IV. Cepheid, 2015. Sunnyvale, California,
USA). To do this, the swabs were first introduced in a NaCl
0,9% solution and vortexed for 3x15 s. Then, 1 mL of each
sample was transferred to the cartridge and ran on the
four-module GeneXpert machine. The GeneXpert HPV
analysis consists of a real-time polymerase-chain-reaction
(PCR) which uses, as an internal assay control for specimen
adequacy, the detection of a Human reference gene (HMBS
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[hydroxymethylbilane synthase]) and an internal Probe
Check Control (PCC). The PCC verifies reagent rehydra-
tion, PCR tube filling in the cartridge, probe integrity, and
dye stability. This test includes reagents that allow the sim-
ultaneous detection of 14 hrHPV types (HPV16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The assay uses
multiple fluorescent channels in order to detect individual
types of HPV, groups of HPV, and the human reference
gene. When sufficient signal is detected by the human
reference gene, the assay results are reported as overall
“positive”. In addition, if HPV16 and pooled HPV 18/45,
together with other high-risk types are detected by the
assay, the result will be labeled as either “positive” or “nega-
tive”. The HPV test results were available in less than an
hour and the test was done on site, enabling us to screen,
triage and treat women on the same day. The use of
GeneXpert as a front-line cervical cancer screening test has
been validated in a recently published study, which
concluded that its performance and reproducibility are
comparable to those of well-established HPV assays [8].
After obtaining the results of the sample analysis, HPV-
negative women were advised to repeat screening after
5 years. HPV-positive women were invited to undergo
visual inspection with acetic acid (VIA) as a triage test.
Visual Inspection with Lugol’s Iodine (VILI) was also per-
formed in order to aid delineate the pathological areas.
VIA and VILI were performed by three trained local gyne-
cologists. VIA consists in the application of a 4% acetic
acid solution on the cervix, which may cause a slight
burning sensation for a few minutes. The appearance of
aceto-white areas touching the squamo-columnar junc-
tion (SCJ) helps define the pathological areas of the cer-
vix. VILI consists in the application of Lugol’s iodine on
the cervix, which does not cause any discomfort. The
appearance of a well-defined, bright yellow area touch-
ing the SCJ defines the presence of a suspicious lesion.
The application and interpretation of VIA and VILI
were conducted according to the World Health Organi-
zation’s recommendations.
Women who were either “HPV-16/18/45-positive” or
“positive to HPV-other high-risk types (HR-HPV) and to
VIA” were considered as screen-positive, thus requiring
treatment. Screen-positive women were considered eli-
gible for thermocoagulation if (i) the lesion extended it-
self less than 2 mm in the endocervical canal, (ii) the
anatomy of the cervix allowed to treat the entire lesion
(multiple applications were possible), (iii) the lesion did
not extend onto the vaginal wall, and (iv) if there was no
suspicion of invasive cancer. No anesthetic prior to the
procedure was administered. Treatment was performed
using the thermocoagulator (WISAP® Medical Technology
GmbH, Brunnthal/Hofolding, Germany) after delineation
of the lesion using Lugol’s iodine. Treatment was per-
formed with a probe heated to 100 °C, which was applied
on the cervix for a period of 60 s. If necessary, the applica-
tion was repeated in order to treat the entire abnormal
area. After usage, the probe was washed with cold water,
dried and heated for about 45 s at 120 °C to sterilize it. A
cervicography of the cervix was undertaken before and
after treatment for quality control.
Outcome measures and follow-up
The primary outcome was the proportion of screen-
positive women who were eligible for thermocoagula-
tion. At the end of the procedure, the physician had to
report whether any complications had taken place, as well
as whether treatment had been completed specifying, if
not, the reason why it had to be interrupted.
The secondary outcomes were the procedure’s side
effects. The discomfort felt throughout thermocoagula-
tion was assessed immediately after treatment by asking
participants to report if they had felt pain, and to specify
its intensity through the visual analogue scale (VAS).
They had to indicate a point on a 10-cm line, with 0
meaning the procedure was not painful at all and 10
meaning it was the most painful experience one could
imagine.
All treated women were invited for a follow-up visit at
1 month. The women’s subjective assessment of symptoms
and side effects, as well as their duration in time, were reg-
istered. A vaginal examination was performed on all partici-
pants in order to exclude any infection and/or wound
healing problem. Cervicography was also undertaken
throughout this visit. Figure 1 shows the photographs taken
on the native cervix, right after thermocoagulation treat-
ment, and at the 1-month control visit.
Fig. 1 Picture of the native cervix
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Data analysis and statistics
Data were analyzed with a statistical analysis software
package StataCorp. 2013 (Stata Statistical Software:
Release 13, College Station, TX, USA).
Quantitative variables were expressed as means and
standard deviations, and qualitative variables were
expressed as percentages, unless otherwise stated.
Descriptive analyses were carried out in order to com-
pare women by their socio-demographic characteristics,
reproductive and sexual history, disease status and
other aspects. Categorical variables were analyzed by
Pearson’s chi-square or Fisher’s test and continuous and
ordinal variables with the Mann-Whitney U-test or the
Kruskal-Wallis test, when appropriate. All hypotheses




A total of 1012 women underwent primary screening
through HPV self-sampling. Sixty-one (6.0%, 95%CI:4.7–
7.7) participants among those who underwent screening
were positive for HPV-16/18/45, and were thus referred
directly for treatment, while 126 (12.4%, 95%CI:10.6–
14.6) women were positive for other HR-HPV types.
Two of these women did not follow through with triage
by VIA and VILI, corresponding to a dropout of 1.6%
(95%CI:0.1–6.0). Among the 124 women who underwent
triage with VIA, 60 (48.4%, 95%CI:39.8–57.1) of them
were positive to these tests and were thus referred for
treatment. Overall, 121 out of 187 HPV-positive women
(64.7%, 95%CI:57.6–71.2) had a positive screen and were
referred to further management. The characteristics of
all screened women are reported in Table 1.
Primary outcome-percentage of screen-positive women
who met cold coagulation criteria
Overall, 110 out of 121 (90.9%, 95%CI:84.3–95.0) screen-
positive women were considered eligible for thermocoagu-
lation and treated. No patients discontinued treatment be-
cause of pain or other adverse effects. A total of 8 (7.3%,
95%CI:3.5–13.9) patients were ineligible for thermocoagu-
lation. Ineligibility reasons included inability to identify
the cervix, no visualization of the SCJ or the presence of a
lesion going more than 2 mm inside the cervix (n = 5),
and having a lesion suspicion of cancer (n = 3). Three
(2.7%) patients were excluded from the study. These in-
clude 2 women not identified as pregnant at the time of
enrolment due to an inclusion error and one who could
not be treated because of a technical issue due to impossi-
bility of heating the probe. Patients with large pathological
areas or having a lesion suspicious for cancer were
referred to LEEP or hysterectomy. Pregnant patients were
invited for a follow-up visit after childbirth.
Secondary outcomes—procedure’s side effects
The participants were asked to quantify the discomfort
felt throughout thermocoagulation using the VAS. A
Table 1 Socio-demographical characteristics and obstetric and
gynecological h istory of the screened population
Variable N %
Total number of women screened 1012





≥ 45 241 23.9
Marital Status
Without a partner 55 5.5
With a partner 954 94.6
Education
Unschooled 7 0.7
Primary education 223 22.1
Secondary education 618 61.3





Age at menarche (mean ± SD), y 14.8 ± 1.9
Age of first sexual intercourse (mean ± SD), y 18.0 ± 2.8
Number of sexual partners (mean ± SD) 3.7 ± 2.7
Number of pregnancies, (mean ± SD) 5.5 ± 2.3
Number of children (mean ± SD) 4.5 ± 1.9
Age at first delivery (mean ± SD), y 21.8 ± 4.0
Contraception
Pill/Injectable/Intrauterine device/Implanon/Other 186 18.4
Condom 111 11.0
None 709 70.5




HPV 16 18 9.6
HPV 18/45 27 15.5
Other HR-HPV 124 66.8
HPV-16 and other HR-HPV 2 1.1
HPV-18/45 and other HR-HPV 13 7.0
VIA/VILI status among other HR-HPV positive women
Pathological 60 48.4
Non pathological 64 51.6
Abbreviations: SD standard deviation, y years, HPV human papillomavirus
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mean ± standard deviation (SD) pain score of 3.0 ± 1.6 was
reported. Thermocoagulation never had to be interrupted
because of pain. Table 2 reports the results of the thermo-
coagulation assessment immediately after treatment.
Adverse events
No serious adverse events occurred during the proced-
ure or in the 30 days following treatment. Three patients
(2.8%) consulted prior to the 1-month control visit be-
cause of important vaginal discharge, and a vaginal anti-
biotic therapy was prescribed to them.
Impact of socio-demographics and obstetric and
gynecological history on pain assessment
Table 3 reports the association of pain according to socio-
demographics and past obstetric and gynecological his-
tory. The patient’s age did not have a significant impact on
pain perception. Women with 2 or more children were
more likely to feel less pain compared to those who had
only one or no children (2.9 ± 1.5 vs 4.2 ± 2.0, p = 0.016).
Follow-up at 1 month
The 1-month follow-up was achieved for 109 out of 110
treated patients, corresponding to a drop out of 0.9%
(95%CI:<0.0001–5.5). Overall, 34 (31.2%, 95%CI:23.2–40.4)
patients reported having felt some degree of pain, mainly
during the first few days following treatment, while 75
(68.8%, 95%CI:59.6–76.8) women did not experience any.
The mean ± SD pain intensity was 0.8 ± 1.4, with a mean ±
SD duration of 2.0 ± 4.2 days. Vaginal discharge, sometimes
with little blood, was reported in 108 out of 109 (99.1%,
95%CI:94.5–100.0) patients, with a mean ± SD duration of
16.2 ± 8.4 days. Adequate wound healing was reported in
100 out of 109 (91.7%, 95%CI:84.9–95.8) women; the
remaining ones showed delayed cervical healing and were
prescribed a local antibiotic. These results are also reported
in Table 2.
Figures 1, 2 and 3 show sequential pictures of the
cervix before, immediately after treatment, and as at
the 1-month follow-up visit, respectively.
Discussion
In a sample of more than 1000 women participating in
an HPV-based cervical cancer screening campaign, most
Table 2 Thermocoagulation assessment immediately after








Not specified 2 1.8
VAS pain score (mean ± SD) 3.0 ± 1.6
VAS pain score (median, range) 2 (1–8)
Desire of future pregnancy 54 49.1
At the 1-month
control visit






VAS pain score (mean ± SD) 0.8 ± 1.4










Table 3 VAS score according to socio-d emographics and
obstetric and gynaecological history
Variable Mean ± SD p value
Age groups, y 0.5
30–34 3.0 ± 1.7
35–39 3.3 ± 1.6
40–44 2.8 ± 1.7
≥ 45 2.8 ± 1.4
Marital Status 0.08
Without a partner 3.7 ± 1.3
With a partner 3.0 ± 1.6
Education 0.844
Unschooled 0
Primary education 2.8 ± 1.2
Secondary education 3.1 ± 1.7
Tertiary education 3.0 ± 1.7
Work 0.84
Employee 3.2 ± 1.8
Independent 3.1 ± 1.8
Housewife 2.8 ± 1.4
Farmer 2.4 ± 0.8
Other 3.4 ± 1.7
Number of sexual partners 0.411
0–4 3.1 ± 1.6
≥ 5 2.9 ± 1.6
Number of children 0.016
0–1 4.2 ± 2.0
≥ 2 2.9 ± 1.5
Abbreviations: SD standard deviation, y years
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screen-positive participants met the criteria to undergo
thermocoagulation in the context of a screen-and-treat
approach, with less than 10% of them not fulfilling the eli-
gibility criteria and needing to be referred for LEEP or a
more radical type of CC treatment. These results are com-
parable to those obtained in a VIA-based cervical cancer
screening campaign involving 6 African countries and
almost 20,000 screened women, where 87.7% of VIA-
positive women were considered eligible for cryotherapy
[9]. Another study conducted in Peru found that 83.8% of
women screened as positive upon HPV testing and triage
by VIA were suitable candidates for cryotherapy [10].
According to our experience, thermocoagulation is a
quick and easy procedure to learn and perform in the
African context. The thermocoagulator costs approximately
the same as a small cryosurgical unit [11]. When compared
to cryotherapy, its potential advantages in clinical practice
include (i) the possibility to precisely destruct the abnormal
area under direct visual control, (ii) the possibility to treat
large abnormal areas in their entirety with several applica-
tions of the probe, and (iii) the fact that it requires a shorter
treatment time than cryotherapy. Finally, like cryotherapy,
it does not require anesthesia [12].
Our triage algorithm allowed all HPV-16/18/45-positive
women, who have a higher risk of CIN2+ when compared
to women positive for other HR-HPV genotypes to be
promptly treated, whereas women positive for other HR-
HPV types were only treated in presence of pathological
VIA/VILI [13]. This type of management was applied in
an effort to reduce the rate of overtreatment by selecting,
among HPV-positive women, those who have a higher risk
of presenting CIN [14].
No patients in our study discontinued treatment
because of pain or other adverse effects, thus demonstrat-
ing that thermocoagulation is a low-pain procedure that
can be successfully carried out until the end if patients are
correctly informed and sufficiently cooperative [15].
Women generally expressed minimal discomfort, and
those who experienced pain described it essentially as
lower abdominal cramping, which was felt mainly during
the procedure and immediately after it. As the main side
effects associated to the procedure, such as bleeding and
vaginal discharge, mostly occur between 1 and 6 weeks
following thermocoagulation, all patients were asked to
come for a control visit at 1 month following treatment
[16, 17]. At this follow-up visit, almost all treated women
reported having experienced a watery vaginal discharge,
seldom with little blood, for about 2 weeks, while only a
few of them experienced abdominal pain. No complica-
tions requiring hospitalization, such as pelvic inflamma-
tory disease or other issues, took place.
Strengths of this study are represented by the fact that it
describes the main key points associated with this quite
unexplored technique in the context of sub-Saharan
Africa. In addition, we have assessed the eligibility or par-
ticipants for thermocoagulation and the overall feasibility
of this technique in the context of a CC screen-and-treat
program. Finally, we have a minimal loss to follow-up at
1-month, which allows us to validate the low complication
rate in the 30 days that follow treatment. Limitations that
need to be addressed are the short follow-up period and
the absence of results regarding the cure rate.
Fig. 2 Picture of the cervix right after treatment with thermocoagulation
Fig. 3 Picture of the cervix at the 1-month control visit
following thermocoagulation
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This is one of the largest studies conducted in LMIC on
the use of thermocoagulation for the treatment of cervical
precancerous lesions. The aim of this pragmatic and
descriptive analysis is to improve knowledge about a pro-
cedure that is potentially widely applicable in LMIC for
the management of screen-positive women. Further pro-
spective studies should focus on evaluating the long-term
efficacy of thermocoagulation in preventing the develop-
ment of CIN and CC, as well as its impact on fertility in
LMIC. In our series, about half of the women still wished
to become pregnant in the future, and the health care pro-
vider has to take this aspect into consideration. To date,
there aren’t any known adverse effects of thermocoagula-
tion on fertility, but this issue still needs to be investigated
with long-term follow-up studies [7].
Conclusions
The high availability of thermocoagulation, together with
its efficacy, renders it a valuable option for the treatment
of screen-positive women in LMIC, such as those in
sub-Saharan Africa [11, 18, 19]. The simplicity of this
intervention may encourage the shift of this type of
treatment from hospital-based environments to commu-
nity settings, as the device weights approximately 2 kg
and is thus easy to move and, globally, ideal for all re-
mote areas that dispose of electricity. Further research
should focus on the achievable cure rates and its impact
on fertility in order to determine if thermocoagulation,
rather than cryotherapy, may become the new gold
standard for treatment of screen-positive women in the
sub-Saharan context.
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